Vendor Intelligence Report: YB Peptide

Executive summary

Across 18 Finnrick lab tests, YB Peptide records 15 passes and 3 failures, an overall pass rate of 83%. The useful signal is not vendor-wide consistency; it is product separation. Retatrutide is the defensible side of the tested catalog, while Tesamorelin is the weak spot and BPC-157 sits in the middle. The full charts also show the weaker products becoming more fragile under stricter grading.

The OSINT record makes YB difficult to treat as an established manufacturer. Its site uses 20-plus-year experience language, but the domain, certificate, Wayback, and asset-timestamp records point to a new 2025 storefront. Registry and web-filing checks also failed to verify the displayed company name, leaving buyers with limited recourse if a parcel fails, a vial tests poorly, or a batch is disputed.

Reverse-IP, CMS, and boilerplate evidence connect YB to three other peptide storefronts, with matching About-page language between at least two brands. That is not proof of one beneficial owner, but it changes diligence: a buyer may be looking at a template-driven sales cluster rather than a stand-alone manufacturer.

The operating model compounds the traceability gap: orders route through WhatsApp and free Aliyun email, while investigators found no public COA archive, batch lookup, GMP certificate number, or physical address. The reputation surface is thin but noisy: no organic review base surfaced, while SEO content farms published fabricated praise and invoked non-existent Finnrick data. The affiliate scan, by contrast, found no X, Reddit web-search, referral-code, or coupon amplification in the searched channels.

Inside the full report:

• Appendix A laboratory table, rating trajectories, and methodology-divergence charts for all three tested products
• Dated domain, certificate-transparency, Wayback, and site-build trail compared with the 20-plus-year experience claim
• Corporate-identity checks across Hong Kong registry sources, OpenCorporates, and ICP lookup results
• Reverse-IP and CMS/template analysis mapping YB, SM, LD, and DH Peptide as a storefront cluster
• Ordering, batch-verification, GMP-claim, reputation, and US import-exposure analysis

Risk assessment

• Unverified corporate identity and buyer recourse risk — high: The trade name “YB HEALTHY PEPTIDE CO., LTD” was not found in HK ICRIS/OpenCorporates/ICP searches; no physical address or registered entity is visible for any product.
• Batch-authentication and GMP-claim verification risk — high: YB advertises GMP workshops and a quality center but publishes no verifiable GMP certificates, batch-linked COAs, or third-party audits; affects all products despite independent testing on sampled lots.
• Tesamorelin quality-risk — high: Finnrick shows Tesamorelin at 48.27% with 5 tests (3 pass / 2 fail), making it the weakest tested YB product.
• BPC-157 quality-risk — medium: Finnrick shows BPC-157 at 56.66% with 5 tests (4 pass / 1 fail); materially weaker than YB Retatrutide.
• US import-seizure and enforcement risk — high: YB lists Retatrutide/Tirzepatide/Semaglutide/BPC-157/Melanotan-2 style catalog items; FDA import alerts and CBP actions target unapproved peptide shipments, and RUO labels do not ensure clearance.
• Payment and dispute-resolution risk — medium: Orders route through WhatsApp and free Aliyun email rather than a standard checkout, card processor, or escrow; buyer protections are limited.
• Brand-confusion and authenticity-verification risk — medium: YB shares infrastructure/boilerplate with SM, LD, and DH Peptide and does not publish an official-channel list, authorized-reseller list, or COA-verification portal.
• Manufactured-reputation risk — medium: No organic reviews or branded social presence were found; AI SEO pages publish fabricated YB reviews and falsely invoke Finnrick data.